AIM:AGY

Stock Analysis Report

Executive Summary

Allergy Therapeutics plc engages in the research and development of allergy treatments.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.

Share Price & News

How has Allergy Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.3%

AGY

-1.6%

GB Pharmaceuticals

-0.4%

GB Market


1 Year Return

-33.2%

AGY

11.7%

GB Pharmaceuticals

2.9%

GB Market

Return vs Industry: AGY underperformed the UK Pharmaceuticals industry which returned 11.7% over the past year.

Return vs Market: AGY underperformed the UK Market which returned 2.9% over the past year.


Shareholder returns

AGYIndustryMarket
7 Day-3.3%-1.6%-0.4%
30 Day-7.8%-5.3%-1.4%
90 Day0%5.4%-2.1%
1 Year-33.2%-33.2%15.1%11.7%8.0%2.9%
3 Year-52.0%-52.0%44.2%30.1%18.0%3.6%
5 Year-37.3%-37.3%83.8%53.5%35.8%6.4%

Price Volatility Vs. Market

How volatile is Allergy Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Allergy Therapeutics undervalued compared to its fair value and its price relative to the market?

21.45x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGY is poor value based on its PE Ratio (21.4x) compared to the Pharmaceuticals industry average (21.4x).

PE vs Market: AGY is poor value based on its PE Ratio (21.4x) compared to the UK market (16.8x).


Price to Earnings Growth Ratio

PEG Ratio: AGY's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: AGY is good value based on its PB Ratio (2x) compared to the GB Pharmaceuticals industry average (2.6x).


Next Steps

Future Growth

How is Allergy Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-40.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGY's earnings are forecast to decline over the next 3 years (-40.8% per year).

Earnings vs Market: AGY's earnings are forecast to decline over the next 3 years (-40.8% per year).

High Growth Earnings: AGY's earnings are forecast to decline over the next 3 years.

Revenue vs Market: AGY's revenue (7.4% per year) is forecast to grow faster than the UK market (3.9% per year).

High Growth Revenue: AGY's revenue (7.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AGY is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Allergy Therapeutics performed over the past 5 years?

-8.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AGY's earnings have declined by -8% per year over the past 5 years.

Accelerating Growth: AGY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AGY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.9%).


Return on Equity

High ROE: AGY's Return on Equity (9.2%) is considered low.


Return on Assets

ROA vs Industry: AGY's Return on Assets is below or equal to the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: AGY's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Allergy Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AGY's short term assets (£46.6M) exceeds its short term liabilities (£16.9M)

Long Term Liabilities: AGY's short term assets (46.6M) exceeds its long term liabilities (14.1M)


Debt to Equity History and Analysis

Debt Level: AGY's debt to equity ratio (6.5%) is considered satisfactory

Reducing Debt: AGY's debt to equity ratio has increased from 0.3% to 6.5% over the past 5 years.

Debt Coverage: AGY's debt is well covered by operating cash flow (229.9%).

Interest Coverage: AGY earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: AGY has a high level of physical assets or inventory.

Debt Coverage by Assets: AGY's debt is covered by short term assets (assets are 19.139980x debt).


Next Steps

Dividend

What is Allergy Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage3.1%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate AGY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AGY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AGY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGY's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Allergy Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Manuel Llobet (55yo)

10.3yrs

Tenure

UK£555,870

Compensation

Mr. Manuel Llobet has been the Chief Executive Officer of Allergy Therapeutics plc since July, 2009. Mr. Llobet joined Allergy in September 2009 following the successful refinancing by Azure Ventures Limit ...


CEO Compensation Analysis

Compensation vs. Market: Manuel's total compensation ($USD715.53K) is about average for companies of similar size in the UK market ($USD320.52K).

Compensation vs Earnings: Manuel's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.8yrs

Average Tenure

Experienced Management: AGY's management team is considered experienced (3.8 years average tenure).


Board Age and Tenure

3.3yrs

Average Tenure

59.5yo

Average Age

Experienced Board: AGY's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUK£3,60024 Oct 18
Peter Jensen
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares20,000
Max PriceUK£0.18
BuyUK£26,25024 Oct 18
Nicolas Alexander Wykeman
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares150,000
Max PriceUK£0.17
BuyUK£8,75024 Oct 18
Manuel Llobet
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares50,000
Max PriceUK£0.17

Ownership Breakdown


Management Team

  • Bev Lees

    Group Operations Director

    • Tenure: 3.8yrs
  • Manuel Llobet (55yo)

    CEO & Executive Director

    • Tenure: 10.3yrs
    • Compensation: UK£555.87k
  • Santi Puig

    Business Development Director

    • Tenure: 10yrs
  • Murray Skinner

    Chief Scientific Officer

    • Tenure: 3.8yrs
  • Sue Baker

    Head of Human Resources

    • Tenure: 0yrs
  • Russell Picket

    Group Financial Controller

    • Tenure: 0yrs
  • Nick Wykeman (54yo)

    CFO & Director

    • Tenure: 3.3yrs
    • Compensation: UK£251.38k
  • Sara Goldsbrough

    Company Secretary

    • Tenure: 2.9yrs
  • Simon Piggott

    Head of Clinical Science

    • Tenure: 2.1yrs

Board Members

  • Tunde Otulana (62yo)

    Independent Non-Executive Director

    • Tenure: 2.3yrs
    • Compensation: UK£40.00k
  • Peter Jensen (68yo)

    Independent Chairman

    • Tenure: 9yrs
    • Compensation: UK£94.00k
  • Mary Tavener (57yo)

    Non-Executive Director

    • Tenure: 0.3yrs
  • Stephen Smith (65yo)

    Senior Independent Director

    • Tenure: 0yrs
    • Compensation: UK£48.73k
  • Johannes Ring

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Hendrik Nolte

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Anthony Frew

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Lawrence Du Buske

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Manuel Llobet (55yo)

    CEO & Executive Director

    • Tenure: 10.3yrs
    • Compensation: UK£555.87k
  • Nick Wykeman (54yo)

    CFO & Director

    • Tenure: 3.3yrs
    • Compensation: UK£251.38k

Company Information

Allergy Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Allergy Therapeutics plc
  • Ticker: AGY
  • Exchange: AIM
  • Founded: 1934
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£74.750m
  • Shares outstanding: 636.17m
  • Website: https://www.allergytherapeutics.com

Number of Employees


Location

  • Allergy Therapeutics plc
  • Dominion Way
  • Worthing
  • West Sussex
  • BN14 8SA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGYT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2004
AGYAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPOct 2004

Biography

Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of po ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 20:33
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.